RBC Capital Maintains Sector Perform on Inovio Pharmaceuticals, Lowers Price Target to $5
RBC Capital analyst Gregory Renza maintains Inovio Pharmaceuticals (NASDAQ:INO) with a Sector Perform and lowers the price target from $6 to $5.
Inovio Pharmaceuticals: Q4 Earnings Insights
Inovio Pharmaceuticals (NASDAQ:INO) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the holiday-shortened week before making a comeback.
Thinking About Buying Stock In AMC Entertainment, Romeo Power Or Inovio Pharmaceuticals?
Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders.
Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
10 Biggest Price Target Changes For Friday
Barclays cut Netflix, Inc. (NASDAQ: NFLX) price target from $675 to $425. Netflix shares fell 19.6% to $408.58 in pre-market trading.
B of A Securities Upgrades Inovio Pharmaceuticals to Neutral, Raises Price Target to $10
B of A Securities analyst Geoff Meacham upgrades Inovio Pharmaceuticals (NASDAQ:INO) from Underperform to Neutral and raises the price target from $8 to $10.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 152 companies set new 52-week lows.